Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SIOG 2017 /
Improving eligibility for the elderly in clinical trails

9th - 11th Nov 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.11.17
Views: 920

Dr Stuart Lichtman - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Stuart Lichtman of the Memorial Sloan Kettering Cancer Center, New York talks to ecancer at SIOG 2017 in Warsaw.

He discusses the fact that older patients are underrepresented in clinical trails, some of which may be due to complications such as co-morbidities which makes it harder to take part in these trials.

As cancer treatment methods change, it also becomes more difficult to take part in these trials, leading to a knowledge gap for understanding drug development for elderly patients.

Dr Lichtmann discusses initiatives that have been undertaken to reduce this problem, and increase the eligibility of elderly people in clinical trails. 

This service has been kindly supported by an unrestricted grant from Janssen Oncology.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation